The Business Research Company's Human Respiratory Syncytial Virus Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

HHS Secretary Robert F. Kennedy Jr named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

No writing assistance was utilized in the production of this manuscript. Worldwide, respiratory syncytial virus (RSV) is the most important cause of bronchiolitis and pneumonia in infants.

Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting ...

The World Health Organization (WHO) published its first-ever position paper on immunization products to protect infants against respiratory syncytial virus (RSV) – the leading cause of acute lower ...

As winter settles over Australia, it's not just the drop in temperature we notice - there's also a sharp rise in respiratory illnesses. Most of us are ...